Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist,clopidogrel

Abstract

Antiplatelet compounds interfere with the platelet activation cascade at different levels. The antiplatelet effect of the thienopyridine, clopidogrel, results from antagonism of a platelet ADP receptor, P_2T, resulting in inhibition of platelet activation. This antagonism is non-competitive, irreversible, and results in a 50-70% inhibition of platelet fibrinogen binding. Additionally, clopidogrel may also antagonize the ADP-induced inhibition of adenylate cyclase, possibly resulting in an elevated platelet cyclic adenosine monophosphate level after stimulation by an appropriate agonist, such as prostacyclin. This spectrum of antiplatelet activities is different from that of aspirin. Further, clopidogrel is associated with a reduction in gastrointestinal hemorrhage, making it a valuable therapeutic alternative to aspirin in oral, long-term prevention of atherothrombotic vascular occlusion.

Keywords

ADP atherosclerosis clopidogrel platelet thrombosis

References

Ross R , Fuster V. The pathogenesis of atherosclerosis. In: Fuster V , Ross R , Topol EJ eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, 1996: 411-460.

Antiplatelet Trialists’ Collaboration . Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocar-dial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.

Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-616.

Du X , Ginsberg MH. Integrin aIIbb3 and platelet function. Thromb Haemost 1997; 78: 96-100.

Schafer AL. Antiplatelet therapy. Am J Med 1996; 101: 199-209.

Hellem A. The adhesiveness of human blood platelets in vitro. Scand J Clin Invest 1960; 12: 1-17.

Gaarder A , Jonsen J , Laaland S , Hellem A , Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532.

Born GVR. Platelet aggregation and its reversal. Nature 1962; 194: 927-929.

O’Brien JR. Platelet aggregation. Part II. Some results from a new method of study. J Clin Pathol 1962; 15: 446-451.

10.

Zawilska KM , Born GVR , Begent N. Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits. Br J Haematol 1982; 50: 317-325.

11.

Moritz MW , Reimers RC , Baker RK , Sutera SP , Joist JH. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 1983; 101: 537-544.

12.

Moake JL , Turner NA , Stathopoulos NA , Nolasco L , Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: 1366-1374.

13.

Born GVR. Adenosine diphosphate is a mediator of platelet aggregation in vivo: an editorial view. Circulation 1985; 72: 741-746.

14.

Rao AK , Willis J , Holmsen H. A major role of ADP in thromboxane transfer experiments: studies in patients with platelet secretion defects. J Lab Clin Med 1984; 104: 116-126.

15.

Valles J , Santos MT , Aznar J et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release and recruitment. Blood 1991; 78: 154-162.

16.

Santos MT , Valles J , Marcus AJ et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest 1991; 87: 571-580.

17.

Coade SB , Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989; 65: 531-537.

18.

Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: 835-855.

19.

Gachet C , Hechler B , Léon C , Vial C , Ohlmann P , Cazenave J-P. Purinergic receptors on blood platelets. Platelets 1996; 7: 261-267.

20.

Nurden AT. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Haemostasis 1996; 26(suppl 4): 78-88.

21.

Mills DCB , Puri RN , Hu CJ et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-436.

22.

Gachet C , Cattaneo M , Ohlmann PO et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-444.

23.

Savi P , Combalbert J , Graich C et al. The antiaggregating activity of clopidogrel is due to metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-317.

24.

Yang LH , Fareed J. Vasomodulatory action of clopidogrel and ticlopi-dine. Thromb Res 1997; 86: 479-491.

25.

Humbert M , Nurden P , Bihour C et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: 1532-1543.

26.

Roald HE , Barstad M , Kierulf P et al. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655-662.

27.

Cooper DMF , Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979; 282: 517-518.

28.

Gachet C , Stierle A , Cazenave JP et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and man. Biochem Pharmacol 1990; 40: 229-238.

29.

Defreyn G , Gachet C , Savi P , Driot F , Cazenave JP , Maffrand JP. Ticlopidine and clopidogrel [SR 25990C] selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-190.

30.

Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-261.

31.

Savi P , Herbert J-M , Pflieger AM et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-532.

32.

Kieffer G , Caplain H , Thiercelin JF , Thebault JJ. Tolerance and pharmacological activity of a new antiplatelet agent clopidogrel [SR 25990 C] in normal healthy volunteers after single increasing administrations. Thromb Haemost 1989; 62: 411-411 [abstract].

33.

Caplain H , Kieffer G , Thiercelin JF , Thebault JJ. Tolerance and clinical pharmacology of repeated administration of clopidogrel [SR 25990 C], a new antiplatelet agent, at three dose levels in normal healthy volunteers. Thromb Haemost 1989; 62: 410-410 [abstract].

34.

Bachmann F , Savcic M , Hauert J , Geudelin B , Kieffer G , Cariou R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 1996; 17 (suppl): 263-263.

35.

Herbért JM , Frekel D , Vallee E et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.

36.

Boneu B , Destelle G on behalf of the Study Group . Platelet anti-aggre-gating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-943.

37.

Guillin M-C , Bonnet G , Sissmann J , Neccian J , Dickinson JP. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis. Eur Heart J 1996; 17 (suppl): 161-161.

38.

Gent M , CAPRIE Steering Committee . A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events [CAPRIE]. Lancet 1996; 348: 1329-1339.

39.

Schömig A , Neumann F-J , Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.

40.

Lablanche J-M , McFadden EP , Bonnet J-L et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach on intracoronary stent management. Eur Heart J 1996; 17: 1373-1380.

41.

Yao S-K , Ober JC , McNatt J et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48.

42.

Samama CM , Bonnin P , Bonneau M et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: 500-505.

43.

Yao S-K , Ober JC , Ferguson JJ et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488-H93.

44.

Pierce CH , Houle J-M , Kieffer G , Dickinson JP. Absence of effect of clopidogrel on human hepatic P-450 activities. Eur Heart J 1996; 17(suppl): 160-160 [abstract].

45.

Caplain H , D’Honneur G , Cariou R. Lack of interaction of aspirin (100 mg) with chronic clopidogrel in volunteers. Haemostasis 1996; 26 (suppl 3): 557-557.

46.

Peeters PAM , Crijns WJ , Tamminga WJ et al. Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin. Eur Heart J 1996; 17 (suppl): 160-160 [abstract].

47.

D’Honneur G , Caplain H , Cariou R , Brouard R. Interaction study between clopidogrel and prolonged intravenous heparin administration in young healthy volunteers. Haemostasis 1996; 26 (suppl 3): 554-554.

48.

Forbes CD , Belch JJ , Bridges AB et al. Pharmacodynamic compatability of clopidogrel with atenolol and nifedipine co-medication in patients with atherosclerotic disease. Eur Heart J 1996; 17 (suppl): 160-160 [abstract].

49.

Weber A-A , Reimann S , Schrör K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1998 (in press).